Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hope this Private placement doesn’t ruin the party today
These shrooms are starting to kick in maaaaann
The fear mongering today has been amusing but we all know where this is headed
Quiet; No one knows about this explosion, Watching for entry!!! $$$$
Looking good. Bullish chart and great accumulation with high volume.
LOBE.CA on its way to 30c Canadian..monster mushroomer!!
CANUCK SCAM will be taken down soon!!!
Yeah weekly reversal will take this to NO BID soon! SCAM ALERT! TOXIC RINSE!
LOLOL
Cup and handle on the 1 m forming?
broke through previous resistance level with serious volume!
watch...weekly reversaL.. BIG W OFF THIS BOTTOM!
Mushroom vision quest!!!
here we go mushroomers...all my clients own this gem and we have a ton!!
enjoy the high...im seeing monsters after .15c canadian
I’m so high right now
The next massive mushroom blitz...i'm getting high on this!!
Yes volume really picking up over the last 2 months. GTSIF$
getting close
Unleashing time!
MONSTER PUMP and DUMP!! TOXIC RINSE!!!
ROFLMAO
Sectors heating up. I've watched another schroomer stock go up 10x. GTSIF$
LOBE alive and well....soon to be a monster mushroomer!!
LOBE.CA selling their previous business for 23 million...when that sale goes through....this will explode!!
If you're watching $GTSIF, you've gotta take a look at $SILO https://alphastocknews.com/silo-pharma-silo-stock-to-climb-on-planned-clinical-trial/4880/
Yeah. Their pre clinical research study sure sounds promising. Lol
new symbol...SOBE.CA...watch this little shroomer to be a big mover...accumulation in the works!!
GTSIF: effective Nov. 16,2020 GreenStar Biosciences Corp. will change to Lobe Sciences Ltd.:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
More information in GSTR can be found here:
https://d.valuethemarkets.com/v2/greenstar-GBR001/index.html
GreenStar Biosciences Announces Filing of Third Provisional Patent Application by Eleusian Biosciences
Newsfile Corp.
Newsfile Corp
Additional provisional patent application, strengthens IP portfolio of therapeutics for the treatment of mild traumatic brain injuries (mTBI) with PTSD or PTSD alone.
Vancouver, British Columbia--(Newsfile Corp. - July 23, 2020) - GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) ("GreenStar" or the "Company") is pleased to announce that Eleusian Biosciences Corporation ("Eleusian") has added to its existing intellectual property portfolio by filing a third provisional patent application. This application further expands the portfolio of proprietary psychedelic therapeutics available to GreenStar and strengthens the intellectual property ("IP") portfolio for treatment of neuropsychiatric disorders with psychedelic compounds. As announced on July 21, 2020, GreenStar and Eleusian have entered into a binding definitive share exchange agreement for GreenStar to acquire 100% of Eleusian.
This provisional patent application Serial No.: 63/040,032 is for methods and compositions for treating mild traumatic brain injury/concussion ("mTBI") with post-traumatic stress disorder ("PTSD") or PTSD alone with 3,4-methylenedioxymethamphetamine ("MDMA") plus N-acetylcysteine ("NAC").
In 2017, the United States Food and Drug Administration ("FDA") granted breakthrough therapy designation for MDMA-assisted psychotherapy for the treatment of PTSD. The Multidisciplinary Association for Psychedelic Studies ("MAPS"), has already successfully completed Phase 2 clinical trials for MDMA-assisted psychotherapy for PTSD, where of 107 participants, 68% no longer had PTSD at the 12-month follow up. All participants had chronic treatment-resistant PTSD and had suffered from PTSD for an average of 17.8 years. (https://maps.org/research/mdma/ptsd/phase3). MAPS has obtained the FDA's agreement for an Expanded Access program, which will allow early access to potentially beneficial investigational therapies for people facing a serious or life-threatening condition for whom currently available treatments have not worked, and who are not able to participate in Phase 3 clinical trials. These agreements validate the fact that MDMA can be an effective therapeutic option for people suffering from PTSD. Eleusian management believes their combination of MDMA plus NAC will result in superior efficacy relative to MDMA alone.
As previously announced, Eleusian has a collaboration agreement with the Miller School of Medicine at the University of Miami to work with a multidisciplinary team of scientists and physicians to develop effective therapeutics for the treatment of mTBI with PTSD, or PTSD alone, using psilocybin and NAC. NAC has been shown to be safe and efficacious in a phase I human clinical study treating military personnel who had suffered mTBI. Eleusian intends to discuss with the Miller School of Medicine at the University of Miami the potential to initiate a research program with their same research team studying MDMA plus NAC for the treatment of mTBI with PTSD or PTSD alone.
According to the Centers of Disease Control and Prevention (the "CDCP"), traumatic brain injury ("TBI") is a major cause of death and disability in the United States. According to the CDCP, the number of TBI-related emergency department visits, hospitalizations, and deaths increased by 53% from 2006 to 2014. TBI cases can range from mild to severe. Mild TBI is the most prevalent form of TBI and effects can include physical symptoms such as loss of consciousness, headache, nausea, fatigue, dizziness and others, sensory problems such as blurred vision, ringing in the ears and sensitivity to light and sound, and cognitive or mental symptoms such as memory problems, mood changes and feelings of depression. These issues not only affect individuals with TBI, but can also have lasting effects on families and communities. According to the U.S. Department of Veterans Affairs, National Center for PTSD, about 7-8% of the U.S. population will have PTSD at some point in their lives and about 8 million U.S. adults have PTSD during a given year. PTSD is a mental health condition that can affect anyone, with potentially long lasting effects. PTSD and TBI have similar symptoms and often coexist because brain injuries are often sustained in traumatic experiences and there is increasing evidence that mTBI can increase risk for PTSD.
"The goal at Eleusian has been to create a best in class management and scientific team, develop our IP portfolio, and develop medical devices and therapeutics to treat certain brain diseases and promote mental wellness," said Maghsoud Dariani, CSO of Eleusian. "With the success MAPS has been having, we are very excited to add the new provisional patent application using MDMA to our portfolio of intellectual property. The research and use of psychedelics, for the treatment of brain injury, has been gaining significant traction and support recently. With our in-house expertise and collaboration partners at the Miller School of Medicine, we believe our development efforts can result in a groundbreaking treatment for mTBI with PTSD or PTSD alone."
About GreenStar
GreenStar is a growth-oriented technology & services company that provides real estate, financial, management, IP & branding support to businesses. The Company operates a growing portfolio of tenant partner companies focused on developing transformational medicines and applies refined strategies to help partner companies reach their full potential. Based in Vancouver, BC, GreenStar intends to facilitate growth through acquisitions and development of additional assets, products and technologies by leveraging its capital markets, branding and operational expertise.
About Eleusian
Eleusian Biosciences Corp., a Toronto based company, is focused on development of therapeutics for multiple pathological psychological diseases based on psychedelic compounds including psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) plus N-Acetylcysteine (NAC) compounds. Eleusian is collaborating with a multidisciplinary team of scientists and physicians at the Miller School of Medicine at the University of Miami to develop effective therapeutics for the treatment of mTBI (mild traumatic brain injury/concussion) with PTSD or PTSD alone based on Psilocybin (the active ingredient of psychedelic mushrooms) and NAC or MDMA and NAC. NAC has been shown to have efficacy in treating mTBI, particularly in reducing neuronal losses and also reducing impaired cognitive and neurological symptoms after injury to head. For more information, visit the company's website at www.eleusian.bio.
Big bidder at .062 and buys at .065 now - looking good.
Eleusian is a private company focused on the development of medical devices and therapeutics for specific
diseases. It is collaborating with a multidisciplinary team of scientists and physicians at the Miller School
of Medicine at the University of Miami to develop effective therapeutics for the treatment of mild traumatic
brain injury/concussion (“mTBI”) with post-traumatic stress disorder (“PTSD”) or PTSD alone, using
psilocybin and N-Acetylcysteine (“NAC”). NAC has been shown to be safe and efficacious in a phase I
human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to
demonstrate the efficacy of the combination of psilocybin and NAC in the treatment of mTBI with PTSD
in established rodent models. The research team at the Miller School of Medicine has a license from the
United States Drug Enforcement Administration to conduct research using Schedule I controlled
substances, which includes psilocybin.
The Eleusian management team includes seasoned capital markets and life sciences executives. CEO and
director, Jonathan Gilbert, had a successful prior exit in the psychedelic space and was the CEO of Scythian
Biosciences, Inc., a publicly traded research and development company focusing on the prevention and
treatment of concussions and traumatic brain injury using a proprietary cannabinoid combination. Mr.
Gilbert is also experienced in strategic investments and partnerships related to the cultivation, distribution
and retail sale of legal cannabis.
Maghsoud Dariani, Chief Science Officer, has years of expertise with life sciences companies. He is
currently also President and CEO of Semorex Inc., a privately held company focused on the discovery and
development of novel therapeutics for cancer. Prior to joining Semorex, Mr. Dariani was President of Focus
Pharmaceuticals, Inc., where he managed the development and approval of drug products, achieving an
FDA approval and bringing another to the clinical evaluation stage. He subsequently negotiated the
successful sale of the company in February 2003. Prior to Focus, Mr. Dariani was Vice President of the
chiral pharmaceutical business unit at Celgene Corporation. During histwelve years at Celgene, Mr. Dariani
was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin,
which are currently marketed by Novartis under the Focalin and Focalin XR trade names.
Yep...looking good
Please PM me... GLTA
Major players coming in with Eleusian -
Transaction Highlights:
- Brings seasoned pharmaceutical leader and executive to GreenStar: Maghsoud Dariani, Eleusian’s
Chief Science Officer to join GreenStar’s executive team as Chief Science Officer
- Eleusian expands GreenStar’s portfolio of brands in the life sciencesspace, capitalizing on the emerging
psychedelic medicine sector
- Provides development opportunities with brain health and mental wellness – pre-clinical trials to lead
to IND submission
- Expands intellectual property portfolio with Eleusian’s provisional patent applications filed in the
United States
.10+ on the way
About GreenStar
GreenStar is a growth-oriented technology and services company that provides real estate, financial, management, IP and branding support to businesses. The Company operates a growing portfolio of tenant partner companies focused on transformational medicine and applies refined strategies to help partner companies reach their full potential. Based in Vancouver, BC, GreenStar intends to facilitate growth through acquisitions and development of additional assets, products and technologies by leveraging its capital markets, branding and operational expertise.
About Eleusian
Eleusian Biosciences Corp., a Toronto based company, is focused on development of therapeutics for multiple pathological psychological diseases based on psilocybin plus N-Acetylcysteine (NAC) compounds. Eleusian is collaborating with a multidisciplinary team of scientists and physicians at the Miller School of Medicine at the University of Miami to develop effective therapeutics for the treatment of mTBI (mild traumatic brain injury/concussion) with PTSD or PTSD alone based on Psilocybin (the active ingredient of psychedelic mushrooms) and NAC. NAC has been shown to have efficacy in treating mTBI, particularly in reducing neuronal losses and also reducing impaired cognitive and neurological symptoms after injury to head. For more information, visit the company's website at www.eleusian.bio.
GreenStar Biosciences Signs Definitive Agreement to Acquire 100% of Eleusian Biosciences Corp.
Strategic acquisition by GreenStar to add innovative company focused on the development of effective therapeutics using psychedelic medicine
Vancouver, British Columbia--(Newsfile Corp. - July 21, 2020) - GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) ("GreenStar" or the "Company") is pleased to announce, further to its press release dated June 16, 2020, that it has signed a definitive binding share exchange agreement dated July 20, 2020 (the "Agreement") to acquire 100% of Toronto, Ontario-based Eleusian Biosciences Corp. ("Eleusian") (the "Transaction") through the issuance of common shares of GreenStar. This Agreement supersedes the previously announced non-binding letter agreement.
Transaction Highlights:
- Brings seasoned pharmaceutical leader and executive to GreenStar: Maghsoud Dariani, Eleusian's Chief Science Officer to join GreenStar's executive team as Chief Science Officer
- Eleusian expands GreenStar's portfolio of brands in the life sciences space, capitalizing on the emerging psychedelic medicine sector
- Provides development opportunities with brain health and mental wellness - pre-clinical studies to lead to IND submission
- Expands intellectual property portfolio with Eleusian's provisional patent applications filed in the United States
Eleusian is a private company focused on the development of medical devices and therapeutics for specific diseases. It is collaborating with a multidisciplinary team of scientists and physicians at the Miller School of Medicine at the University of Miami to develop effective therapeutics for the treatment of mild traumatic brain injury/concussion ("mTBI") with post-traumatic stress disorder ("PTSD") or PTSD alone, using psilocybin and N-Acetylcysteine ("NAC"). NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the efficacy of the combination of psilocybin and NAC in the treatment of mTBI with PTSD in established rodent models. The research team at the Miller School of Medicine has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.
The Eleusian management team includes seasoned capital markets and life sciences executives. CEO and director, Jonathan Gilbert, had a successful prior exit in the psychedelic space and was the CEO of Scythian Biosciences, Inc., a publicly traded research and development company focusing on the prevention and treatment of concussions and traumatic brain injury using a proprietary cannabinoid combination. Mr. Gilbert is also experienced in strategic investments and partnerships related to the cultivation, distribution and retail sale of legal cannabis.
Maghsoud Dariani, Chief Science Officer, has years of expertise with life sciences companies. He is currently also President and CEO of Semorex Inc., a privately held company focused on the discovery and development of novel therapeutics for cancer. Prior to joining Semorex, Mr. Dariani was President of Focus Pharmaceuticals, Inc., where he managed the development and approval of drug products, achieving an FDA approval and bringing another to the clinical evaluation stage. He subsequently negotiated the successful sale of the company in February 2003. Prior to Focus, Mr. Dariani was Vice President of the chiral pharmaceutical business unit at Celgene Corporation. During his twelve years at Celgene, Mr. Dariani was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin, which are currently marketed by Novartis under the Focalin and Focalin XR trade names.
Terms of the Agreement
Pursuant to the Agreement, Eleusian shareholders will receive total consideration of $3,010,028 through the issuance on a pro-rata basis of an aggregate of 60,200,056 common shares of GreenStar (each a "GreenStar Share") at a deemed issue price of $0.05 per GreenStar Share, on the basis of approximately 3.126 GreenStar Shares for every one (1) Eleusian share. All GreenStar Shares to be issued will be subject to contractual restrictions on transfer, pursuant to which 25% of the GreenStar Shares issued will be transferable on the closing of the Transaction and further 25% will become transferable every three months thereafter (subject to compliance with all applicable securities laws). The Company will pay a finder's fee of 5%, to be settled by the issuance of 3,010,002 GreenStar Shares, to an arm's-length finder in connection with the closing of the Transaction. In addition to Mr. Dariani joining GreenStar as its Chief Science Officer, on closing, Eleusian will have the right to appoint one nominee to the GreenStar board of directors.
The Transaction is subject to standard closing conditions, including final due diligence by the parties and receipt of applicable corporate and regulatory approvals. There can be no assurances the Transaction will be completed as proposed or at all. The Company anticipates closing the Transaction prior to August 1, 2020.
"With its experienced team and collaboration partners, we believe Eleusian will prove to be a market leader developing unique and proprietary technologies, as already evidenced by its current IP portfolio and development work," said Thomas Baird, GreenStar CEO. "GreenStar and Eleusian have very complementary assets and skill sets, and we look forward to working together to accelerate growth. We aim to develop new treatments and make a difference for people suffering from PTSD and brain injuries."
The Transaction will be completed pursuant to exemptions from the prospectus and registration requirements under applicable securities laws. None of the GreenStar Shares issued to Eleusian shareholders in connection with the Transaction will be registered under the United States Securities Act of 1933, as amended, and none may be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any GreenStar Shares, nor shall there be any distribution of GreenStar Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About GreenStar
GreenStar is a growth-oriented technology and services company that provides real estate, financial, management, IP and branding support to businesses. The Company operates a growing portfolio of tenant partner companies focused on transformational medicine and applies refined strategies to help partner companies reach their full potential. Based in Vancouver, BC, GreenStar intends to facilitate growth through acquisitions and development of additional assets, products and technologies by leveraging its capital markets, branding and operational expertise.
About Eleusian
Eleusian Biosciences Corp., a Toronto based company, is focused on development of therapeutics for multiple pathological psychological diseases based on psilocybin plus N-Acetylcysteine (NAC) compounds. Eleusian is collaborating with a multidisciplinary team of scientists and physicians at the Miller School of Medicine at the University of Miami to develop effective therapeutics for the treatment of mTBI (mild traumatic brain injury/concussion) with PTSD or PTSD alone based on Psilocybin (the active ingredient of psychedelic mushrooms) and NAC. NAC has been shown to have efficacy in treating mTBI, particularly in reducing neuronal losses and also reducing impaired cognitive and neurological symptoms after injury to head. For more information, visit the company's website at www.eleusian.bio.
For further information please contact:
GreenStar Biosciences Corp.
Thomas Baird, CEO
info@greenstarbiosciences.com
Tel: (604) 834-9499
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
129
|
Created
|
12/06/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |